Landells Fiona M, Vender Ronald
Faculty of Medicine, Memorial University of Newfoundland, St. John's, NL, Canada.
Dermatrials Research Inc., Hamilton, ON, Canada.
SAGE Open Med Case Rep. 2023 Aug 12;11:2050313X231193077. doi: 10.1177/2050313X231193077. eCollection 2023.
Adalimumab is a tumor necrosis factor inhibitor that has been widely used since the early 2000s for the treatment of psoriasis and psoriatic arthritis. All tumor necrosis factor inhibitors have been identified as causative agents in drug induced lupus, particularly etanercept and infliximab. There have been few reported cases of systemic lupus erythematosus induced by adalimumab, many more are attributable to treatment with etanercept or infliximab. We present the case of a patient with long-standing psoriasis and psoriatic arthritis who was successfully treated with adalimumab, but developed anti-tumor necrosis factor-induced lupus.
阿达木单抗是一种肿瘤坏死因子抑制剂，自21世纪初以来已被广泛用于治疗银屑病和银屑病关节炎。所有肿瘤坏死因子抑制剂都已被确定为药物性狼疮的致病因素，尤其是依那西普和英夫利昔单抗。由阿达木单抗引起的系统性红斑狼疮报告病例较少，更多的是归因于依那西普或英夫利昔单抗治疗。我们报告了一例患有长期银屑病和银屑病关节炎的患者，该患者用阿达木单抗成功治疗，但发生了抗肿瘤坏死因子诱导的狼疮。
